Tag Archives: coronary disease

ESC guidelines and differences between NOACs Following the roll-out of the novel oral anticoagulants (NOACs), the European Society of Cardiology (ESC) published in 2012 a focused update of its guidelines for the management of atrial fibrillation (AF). Since the NOACs tested in clinical trials all showed at least non-inferiority when compared with vitamin K antagonists (VKAs), with a better safety profile, particularly with reduction in intracranial haemorrhage (ICH), the ESC 2012 guideline recommended NOACs as broadly preferable to VKAs in the vast majority of patients with non-valvular AF (NVAF).1 In 2013, the European Heart Rhythm Associati

As with the global results, there was a high use of evidence-based therapies in the UK patients. Despite this, the combined incidence of cardiovascular events at one year (cardiovascular death, myocardial infarction, stroke) was high at 4.82%, 4.46% and 4.35% respectively for peripheral arterial disease (PAD), cerebrovascular disease (CVD) and coronary artery disease (CAD). These figures increase markedly when hospitalisations are taken into account, particularly in patients with PAD (18.54%) compared with CVD (8.29%) and CAD (10.07%). Cardiovascular event rates increased significantly with the number of symptomatic locations (p=0.0043), incr

No content available

No content available

No content available